Repurposing rosiglitazone, a PPAR-γ agonist and oral antidiabetic, as an inhaled formulation, for the treatment of PAH.

about

Repurposing rosiglitazone, a PPAR-γ agonist and oral antidiabetic, as an inhaled formulation, for the treatment of PAH.

Item

http://www.wikidata.org/entity/Q53686493

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Repurposing rosiglitazone, a P ...... ion, for the treatment of PAH.

@en

Repurposing rosiglitazone, a P ...... ion, for the treatment of PAH.

@nl

type

Item

label

Repurposing rosiglitazone, a P ...... ion, for the treatment of PAH.

@en

Repurposing rosiglitazone, a P ...... ion, for the treatment of PAH.

@nl

prefLabel

Repurposing rosiglitazone, a P ...... ion, for the treatment of PAH.

@en

Repurposing rosiglitazone, a P ...... ion, for the treatment of PAH.

@nl

P1476

Repurposing rosiglitazone, a P ...... tion, for the treatment of PAH

@en

P2093

Ahmad Alobaida

http://www.w3.org/2001/XMLSchema#string

Eva Nozik-Grayck

http://www.w3.org/2001/XMLSchema#string

Fakhrul Ahsan

http://www.w3.org/2001/XMLSchema#string

Ivan F McMurtry

http://www.w3.org/2001/XMLSchema#string

Kurt R Stenmark

http://www.w3.org/2001/XMLSchema#string

Samia Hammouda

http://www.w3.org/2001/XMLSchema#string

Taslim A Al-Hilal

http://www.w3.org/2001/XMLSchema#string

P2860

Molecular, biochemical and functional characterizations of C1q/TNF family members: adipose-tissue-selective expression patterns, regulation by PPAR-gamma agonist, cysteine-mediated oligomerizations, combinatorial associations and metabolic functions

Process and formulation variables in the preparation of injectable and biodegradable magnetic microspheres.

Hypoxic repression of endothelial nitric-oxide synthase transcription is coupled with eviction of promoter histones

Effect of PPARgamma inhibition on pulmonary endothelial cell gene expression: gene profiling in pulmonary hypertension.

PPAR{gamma} regulates hypoxia-induced Nox4 expression in human pulmonary artery smooth muscle cells through NF-{kappa}B.

Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension.

Tumor necrosis factor-alpha and interleukin-1beta increases CTRP1 expression in adipose tissue.

An antiproliferative BMP-2/PPARgamma/apoE axis in human and murine SMCs and its role in pulmonary hypertension.

Circulating level of CTRP1 in patients with nonalcoholic fatty liver disease (NAFLD): is it through insulin resistance?

Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications.

P304

113-123

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.JCONREL.2018.04.049

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

280

http://www.w3.org/2001/XMLSchema#string

P50

Jahidur Rashid

P577

2018-04-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29723610

http://www.w3.org/2001/XMLSchema#string

P932

5993641

http://www.w3.org/2001/XMLSchema#string